Syndax Pharmaceuticals Inc

Explore Syndax Pharmaceuticals: a biotech leader developing innovative solid‑tumor, lung, breast, and blood‑cancer therapies amid volatile stock swings and growth potential.

Syndax Pharmaceuticals, a biotechnology company, has made significant strides in developing cancer therapies, with a market capitalization of $1.15 billion and a stock price of $13.11 as of October 26, 2025.

Syndax Pharmaceuticals, a biopharmaceutical company, continues to focus on developing therapies for solid tumors and various cancers, with a market capitalization of $1.33 billion and a stock price of $14.3 as of October 16, 2025.

Syndax Pharmaceuticals is set to release its quarterly financial results on August 4, 2025, with analysts expecting a significant revenue surge and a loss per share of -1.016 USD.

Syndax Pharmaceuticals Inc faces financial challenges and declining investor confidence, raising questions about its ability to deliver on its cancer therapy development promises.

Syndax Pharmaceuticals is navigating challenges in the biotech industry with strategic moves, including new leadership and data presentations at EHA 2025, positioning the company for potential breakthroughs in cancer treatment.

Syndax Pharmaceuticals Inc. is preparing to release its Q1 2025 earnings, a highly anticipated event that will provide insights into the company’s financial health and strategic direction in the competitive biopharmaceutical sector.